All In Biotech

Drug Trial Radar · NCT04468971

REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia

Phase 1 Double-Blinded, Randomized, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) In The Treatment Of COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS)

Last checked: Nov 19, 2026Latest source record: Mar 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

Sep 29, 2020

Primary completion

Oct 22, 2021

Study completion Oct 22, 2021

Sponsor

Lead sponsor
Cellenkos, Inc.Industry
Sponsor type
Industry
First posted
Jul 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced moderate-to-severe PNA-ARDS.

Conditions

  • COVID19
  • ARDS

Interventions

  • CK0802Biological

    Cryopreserved, off the shelf, cord blood derived T regulatory cells

  • PlaceboDrug

    Expicient

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Regimen related ≥ grade 3 toxicity within 48 hours of first infusionTime frame: 48 hours
  2. 28-day treatment success, defined as S28Time frame: 28 days

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Columbia University

    New York, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Wake Forest University

    Winston-Salem, North Carolina

  • Baylor College of Medicine, St Luke's Hospital

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.